Cardiovascular research director has been sourced more than 30,000 times.
Dominick Angiolillo, MD, PhD, a professor of medicine and director of cardiovascular research at the University of Florida College of Medicine – Jacksonville, continues to be one of the world’s most-sourced researchers.
Angiolillo appears on a list released this month by Clarivate Analytics, which tracks the number of times scientists are cited in science and social science journals worldwide. Clarivate Analytics is formerly part of Thomson Reuters.
The Highly Cited Researchers list for 2018 accounts for citations over an 11-year span, from the start of 2006 through 2016, and features the scientists who rank in the top 1 percent of their respective field. This is the fifth consecutive year Angiolillo has been included.
“Receiving this recognition is very rewarding,” said Angiolillo, whose work includes extensive research on cardiovascular disease. “The fact that scientists from across the globe continue to reference our research is a clear sign the work we are doing is not only innovative, but is also helping improve patient care.”
Angiolillo is one of 12 UF faculty members to make Clarivate Analytics’ 2018 list. As in each of the previous four years, he is the only person from the College of Medicine, in Jacksonville or Gainesville, to appear on the list. Only two other UF faculty members have made the list five consecutive years.
“The Clarivate Analytics list of Highly Cited Researchers for 2018 identifies scientists and social scientists who have demonstrated significant influence through publication of multiple highly cited papers,” the organization said in a media release. “Researchers are selected for their exceptional performance in one or more of 21 fields or across several fields.”
Angiolillo has authored more than 400 peer-reviewed articles and has been cited more than 30,000 times throughout his career. His research includes ongoing clinical trials at UF Health Jacksonville that target stent-procedure patients. During appointments, his team conducts genetic tests to help determine if individual cardiovascular patients carry certain genes that make them less likely to metabolize clopidogrel, also known as Plavix. That medication is often prescribed to patients following the placement of coronary stents to reduce the risk of blood clots and heart attacks.
When a certain gene is detected, an alternate treatment method is taken.
“We have almost completed our feasibility project of rapid genetic testing,” Angiolillo said. “It’s been very successful and we have set the foundation for a number of ongoing research efforts across the globe that deal with personalized medicine for patients needing blood-thinning medications. Our work has also led to genetic testing being implemented as a standard clinical test at UF Health Jacksonville starting in 2019.”
Dominick J. Angiolillo, MD, PhD, FACC
Medical Director, Cardiovascular Research Program; Program Director, Interventional Cardiology Fellowship Program; Associate Program Director, Cardiovascular Disease Fellowship